Andrew Dorr

1.3k total citations
37 papers, 1.0k citations indexed

About

Andrew Dorr is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew Dorr has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew Dorr's work include PARP inhibition in cancer therapy (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Andrew Dorr is often cited by papers focused on PARP inhibition in cancer therapy (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Andrew Dorr collaborates with scholars based in United States, United Kingdom and Canada. Andrew Dorr's co-authors include Richard S. Geary, Jon Holmlund, T. Jesse Kwoh, John Nemunaitis, Branimir I. Šikić, Casey Cunningham, George A. Fisher, Joanne Halsey, Joan H. Schiller and Elizabeth A. Eisenhauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Andrew Dorr

34 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Dorr United States 16 737 356 147 124 110 37 1.0k
Masamichi Mori Japan 17 524 0.7× 407 1.1× 164 1.1× 131 1.1× 249 2.3× 41 1.1k
L. McIntosh Canada 12 467 0.6× 298 0.8× 171 1.2× 198 1.6× 86 0.8× 22 781
Samuel W. Brady United States 14 608 0.8× 588 1.7× 188 1.3× 74 0.6× 44 0.4× 25 1.1k
Marion T. Weigel Germany 16 481 0.7× 338 0.9× 119 0.8× 41 0.3× 65 0.6× 27 1.1k
Alexander C. Klimowicz Canada 23 821 1.1× 653 1.8× 188 1.3× 49 0.4× 166 1.5× 56 1.5k
Lawrence Panasci Canada 14 311 0.4× 416 1.2× 95 0.6× 61 0.5× 56 0.5× 32 656
Martina Rahmeh Germany 13 476 0.6× 677 1.9× 197 1.3× 109 0.9× 32 0.3× 22 1.2k
A. W. Tolcher United States 19 821 1.1× 583 1.6× 310 2.1× 72 0.6× 59 0.5× 107 1.3k
Vijay Peddareddigari United States 11 714 1.0× 600 1.7× 183 1.2× 63 0.5× 68 0.6× 18 1.2k
Deepika Kanojia India 20 944 1.3× 223 0.6× 150 1.0× 44 0.4× 103 0.9× 26 1.3k

Countries citing papers authored by Andrew Dorr

Since Specialization
Citations

This map shows the geographic impact of Andrew Dorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Dorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Dorr more than expected).

Fields of papers citing papers by Andrew Dorr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Dorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Dorr. The network helps show where Andrew Dorr may publish in the future.

Co-authorship network of co-authors of Andrew Dorr

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Dorr. A scholar is included among the top collaborators of Andrew Dorr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Dorr. Andrew Dorr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2025). Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 43(15). 1824–1834. 5 indexed citations
2.
Cai, Jinjin, Andrew Dorr, Xiaojuan Li, et al.. (2023). Abstract CT117: Synergism between inhibitors of the EGFR-RAS-RAF-MEK pathway and the WNT pathway. Cancer Research. 83(8_Supplement). CT117–CT117.
3.
Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2021). 591P A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S639–S639. 1 indexed citations
4.
Wong, Sandy W., Philip Imus, Tomer M. Mark, et al.. (2021). P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S164–S164. 8 indexed citations
5.
Dunn, Sandra E., et al.. (2020). Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC). Cancer Research. 80(4_Supplement). P3–10. 7 indexed citations
6.
Komrokji, Rami S., John F. Seymour, Andrew W. Roberts, et al.. (2015). Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 125(17). 2649–2655. 95 indexed citations
7.
Bhatt, Rupal S., Sumanta K. Pal, Harry A. Drabkin, et al.. (2014). A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab (LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(15_suppl). TPS4605–TPS4605. 1 indexed citations
8.
Henshaw, Joshua W., Huiyu Zhou, Ashleigh Herriott, et al.. (2013). Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12(11_Supplement). A220–A220. 1 indexed citations
9.
Denlinger, Crystal S., Rebecca Blanchard, Lu Xu, et al.. (2009). Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65(1). 97–105. 21 indexed citations
10.
Šufliarský, Jozef, Jozef Chovanec, Daniela Světlovská, et al.. (2009). Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer. Neoplasma. 56(4). 291–297. 4 indexed citations
11.
Robová, Helena, Lukáš Rob, H Stankusová, et al.. (2004). [Guideline for gynecological malignant tumors 2004--primary complex therapy in operable stages of malignant tumors of vulva].. PubMed. 69(6). 477–83. 1 indexed citations
12.
Advani, Ranjana H., Prema P. Peethambaram, Bert L. Lum, et al.. (2004). A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma. Cancer. 100(2). 321–326. 56 indexed citations
13.
Yu, Rosie Z., John Q. Su, John S. Grundy, et al.. (2003). Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens. Antisense and Nucleic Acid Drug Development. 13(1). 57–66. 17 indexed citations
14.
Oza, Amit M., Laurie Elit, K. Swenerton, et al.. (2003). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆. Gynecologic Oncology. 89(1). 129–133. 55 indexed citations
15.
Tolcher, Anthony W., Leonard Reyno, Peter Venner, et al.. (2002). A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.. PubMed. 8(8). 2530–5. 99 indexed citations
16.
Cunningham, Casey, Jon Holmlund, Richard S. Geary, et al.. (2001). A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer. 92(5). 1265–1271. 71 indexed citations
17.
Arbuck, Susan G., Andrew Dorr, & Michael Friedman. (1994). Paclitaxel (Taxol) in Breast Cancer. Hematology/Oncology Clinics of North America. 8(1). 121–140. 35 indexed citations
18.
Dorr, Andrew. (1990). Adjuvant therapy in breast cancer. Current Opinion in Oncology. 2(6). 1049–1052. 2 indexed citations
19.
Crawford, E. David, et al.. (1987). A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2. European Journal of Cancer and Clinical Oncology. 23(8). 1235–1235. 2 indexed citations
20.
Dorr, Andrew, et al.. (1971). Discriminant function in clinical trials. Clinical Pharmacology & Therapeutics. 12(1). 151–152. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masamichi Mori Breakdown of academic impact, for papers by L. McIntosh Breakdown of academic impact, for papers by Samuel W. Brady Breakdown of academic impact, for papers by Marion T. Weigel Breakdown of academic impact, for papers by Alexander C. Klimowicz Breakdown of academic impact, for papers by Lawrence Panasci Breakdown of academic impact, for papers by Martina Rahmeh Breakdown of academic impact, for papers by A. W. Tolcher Breakdown of academic impact, for papers by Vijay Peddareddigari Breakdown of academic impact, for papers by Deepika Kanojia
Rankless by CCL
2026